Melanoma (stage III/IV)
Conditions
Interventions
None listed
Sponsors
No sponsors, the study is investigator initiated
Eligibility
Inclusion criteria
Inclusion criteria: In order to participate in this study, patients have to be: - At least 18 years of age - Actively treated for melanoma by use of immunotherapy, surgery or a combination. - Willing to fill in one questionnaire and perform one online cognition test.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Insufficient understanding of the Dutch or English language
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be assessed by use of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 is a self-reported questionnaire, specifically developed for patients with cancer who are receiving cancer treatment. The EORTC-QLQ- C30 is widely accepted and validated in clinical studies. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Melanoma (surgery) specific symptoms (Functional Assessment of Cancer Therapy- Melanoma; FACT-M) - Sociodemographic data - Anxiety and depression (Hospital Anxiety and Depression Scale; HADS) - Worry about cancer (Cancer Worry Scale; CWS) - Immunotherapy-related discomforts - Sexual health (EORTC sexuality questionnaire) - Work ability - Quality-adjusted life years (QUALYs) by means of the 5 level EuroQoL-5D - Cognitive status (Amsterdam Cognition Scan) | — |
Contacts
Public ContactNoëlle van den heuvel
The Netherlands Cancer Center
Outcome results
None listed